<DOC>
	<DOCNO>NCT01827579</DOCNO>
	<brief_summary>The purpose study evaluate whether administration allodepleted donor T cell patient haematological malignancy stem cell transplant improve recovery patient immune system .</brief_summary>
	<brief_title>Infusion Depleted T Cells Following Unrelated Donor Stem Cell Transplant ( ICAT )</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Age â‰¥16 year Underlying haematological malignancy Planned allogeneic peripheral blood stem cell transplantation 10/10 9/10 HLA match unrelated donor , use Alemtuzumabbased conditioning protocol Written Informed consent Life expectancy &lt; 6 week Female patient pregnant lactate Patients serologically positive Hepatitis B , C HIV preSCT</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Transplant</keyword>
	<keyword>CD25/71 allodepleted donor T cell</keyword>
	<keyword>Infection</keyword>
	<keyword>Acute Myeloid Leukaemia</keyword>
	<keyword>Acute Lymphoblastic Leukaemia</keyword>
	<keyword>Adult</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
</DOC>